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Recently published WHO guidance recommends starting ART in HIV-infected adults with
CD4 counts of ≤350 cells/μl [1]. There is mounting evidence that such a policy will lead to
lower mortality among HIV-infected individuals [2]. Also modeling data suggests that
expanded testing and earlier treatment will reduce HIV transmission [3]. In South Africa
ART coverage is not meeting current needs, even using the CD4 count criteria of <200 cells/
μl, and mortality early in ART programmes is high due to advanced immunosuppression at
initiation [4]. Fortunately, following limited government leadership around HIV in the past,
South African President Jacob Zuma has encouraged widespread HIV testing, and
announced that he will undertake an HIV test [5].
However, expanded testing will only reduce mortality if patients testing HIV-positive are
effectively and quickly channeled into treatment programmes. Our experience in Cape Town
suggests that even at current levels of testing this is not the case. For the past two years, as
part of ongoing clinical trials of cryptococcal meningitis (CM) treatment, we have
prospectively identified all patients presenting with CM at a secondary level hospital serving
a population of 1.3 million, with free access to HIV-testing and treatment services. As an
opportunistic infection affecting primarily those with CD4 counts of <100 cells/μl, rates of
CM would be expected to decline rapidly in the face of effective ART programmes, as has
been seen in the developed world [6].
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In our setting, despite ART roll-out, annual numbers of CM cases have remained fairly
constant, as the number of patients developing stage 4 disease exceeds the numbers starting
ART [7]. Most patients with CM are ART-naïve [8]; however in contrast to our expectations
the majority (73%, 134 /183) were already known to be HIV-positive. Patients had tested
positive a median of 4 months (IQR 2-12) prior to presentation with CM, and of those with
documented CD4 counts at initial HIV diagnosis, 91% (64/70) were ≤200 cells/μl. Many
patients are being tested, but not treated.
Our findings fit with data showing high mortality and loss to follow-up rates in ART
programmes prior to ART initiation. In a cohort with extremely good retention in Cape
Town, despite a median time from enrollment to ART initiation of only 34 days, almost half
of all deaths in the programme occurred in this pre-treatment period [4]. The situation in
much of the South African public sector is even more concerning. In a large cohort from the
Free State province over 50% of eligible patients never received ART (3774 of 6899). Fifty-
three percent of the cohort died, and 87% of these had not received ART [9].
Establishing why patients are testing but not initiating treatment is difficult. In South Africa
mixed messages regarding safety and efficacy of ART may contribute to poor patient uptake
of existing services [10]. Under-funding of HIV-services, heavy patient loads and long
waiting times are likely to also contribute. Additionally, current guidelines [11, 12]
specifying that patients should return for 3 separate outpatient visits prior to ART initiation,
when transport costs have been identified as a barrier to accessing care in many areas [13],
and encouraging disclosure of a stigmatizing diagnosis to treatment supporters, may
discourage many from accessing care.
While the rationale behind such guidance arose from an urgent need to create effective,
implementable and reproducible ART services, subsequent experience in regions where the
majority of patients present with advanced immunosuppression suggests efforts are now
needed to “fast-track” ART initiation. Initial concerns about adherence in African patients
have been dispelled, with recorded adherence in African cohorts matching or surpassing the
developed world [14]. Evidence for the efficacy of adherence interventions such as repeated
counseling sessions prior to ART, which in practice are often weeks apart, is limited [15].
Nonetheless, in many ART programmes, this seems to outweigh the compelling evidence
demonstrating that even minor delays in ART initiation in patients with advanced HIV leads
to unacceptably high levels of mortality [4, 9].
In settings such as ours, where 22% of patients still present with CD4 counts below 50 cells/
μl [16], current focus on the “workup” prior to ART initiation needs to be shifted to efforts
aimed at quickly establishing vulnerable patients on treatment, coupled with ongoing
adherence support. Linkage from testing to care must be improved, and while there may be a
minority who will not adhere with “fast-track” initiation, the adherent majority will no
longer be exposed to extreme risk of opportunistic infections such as cryptococcal
meningitis, and the associated mortality, while waiting for ART.
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